Portal de investigación
Caracterizacion y repercusion terapeutica de la ecologia de cancer de mama HER2 positivo
Datos básicos
- Protocolo:
- PI18/01219
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA
- Año de incio:
- 2019
- Año de finalización:
- 2021
Documentos
- No hay documentos
Grupos y Plataformas de I+D+i
Financiadores - Promotores
Resultados del Ensayo Clínico
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Pineda, B; (...); Eroles, P
Article. 10.1186/s13148-019-0626-0. 2019
Biocompatibility and internalization assessment of bare and functionalised mesoporous silica nanoparticles
Garrido-Cano, I; (...); Martinez-Manez, R
Article. 10.1016/j.micromeso.2020.110593. 2021
CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer.
Luque, M; (...); Rojo, F
Article. 10.3390/jcm11061610. 2022
Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer.
Adam-Artigues, A; (...); Cejalvo, J M
Article. 10.1016/j.esmoop.2020.100039. 2021
Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.
Garrido-Cano, Iris; (...); Eroles, Pilar
Article. 10.3390/ijms21197427. 2020
Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia.
Ballester, Sandra; (...); Eroles, Pilar
Article. 10.3390/genes11060686. 2020
High numbers of circulating CD57+ NK cells associate with resistance to HER2-specific therapeutic antibodies in HER2+ primary breast cancer.
Muntasell, Aura; (...); Lopez-Botet, Miguel
Article. 10.1158/2326-6066.CIR-18-0896. 2019
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
Torres-Ruiz, Sandra; (...); Eroles, Pilar
Article. 10.3390/ijms24043601. 2023
MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma.
Pattanayak, Birlipta; (...); Eroles, Pilar
Article. 10.3389/fonc.2020.01661. 2020
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano, Iris; (...); Eroles, Pilar
Article. 10.1007/s10555-021-09992-0. 2022
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+Breast Cancer
Cabello, Paula; (...); Eroles, Pilar
Article. 10.3390/cancers15072138. 2023
miR-99a-5p modulates doxorubicin resistance via the COX-2/ABCG2 axis in triple-negative breast cancer: from the discovery to in vivo studies.
Garrido-Cano, Iris; (...); Eroles, Pilar
Letter. 10.1002/cac2.12352. 2022
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
Casadevall, David; (...); Albanell, Joan
Article. 10.1158/1541-7786.MCR-21-0545. 2022
Nanoporous Anodic Alumina-Based Sensor for miR-99a-5p Detection as an Effective Early Breast Cancer Diagnostic Tool.
Garrido-Cano, Iris; (...); Martinez-Manez, Ramon
Article. 10.1021/acssensors.0c02222. 2021
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Guardia, Cristina; (...); Albanell, Joan
Article. 10.1158/1078-0432.CCR-20-2915. 2021
Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.
Luque, M; (...); Rojo, F
Article. 10.3390/ijms222413297. 2021
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.
Adam-Artigues, A; (...); Cejalvo, JM
Article. 10.1126/sciadv.abk2746. 2022
The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
Tormo, E; (...); Eroles, P
Article. 10.1038/s41598-019-41472-y. 2019
The nuclear retinoid-related orphan receptor RORa controls adipose tissue inflammation in patients with morbid obesity and diabetes.
Ortega, Rebeca; (...); Piqueras, Laura
Article. 10.1038/s41366-021-00787-5. 2021
